1/74
Looks like no tags are added yet.
secretory products from living cells
soluble factors, extracellular vesicles, and membrane-less EVs
soluble factors
proteins, neurotransmitters, metabolites
membrane-less EVs (extracellular vesicles)
exomere, supermeres, condesates, chromatomeres
extracellular vesicles
lipid bilayer bound, exosomes, ectosomes/microvesicles, apoptotic bodies
when are apoptotic bodies usually released?
when cell is dying
ectosomes released by different types of cells are _
called by different names
retinoic acid
can differentiate pluirpotent P19 cells into P19 neurons
PNGaseF
reduces size of amino acids
how is purification of exosomes done?
differential centrifugation
what gene is not in exosomes?
tsg101
CD63
gene on cell surface of exosomes
Dil
dye that labels exosomes
UD-P19 and P19N internalize
P19N exosomes
what can P19 exosomes do?
induce differentiation of UD-P19 to P19 neurons, UD-P19 exosomes will NOT do this
MAP2 antibody
microtubule protein found in post-mitotic neurons
there is differential expression of _ in UD-P19
ncRNAs
folic acid deficiency in fetus
starts with BMP and Wnt signaling pathway, fetus has to be aborted
what are exosomes natural function?
cellular communication
where can exosomes be sourced from?
blood, urine, saliva, cell culture
how can exosomes be engineered?
surface modification to send them to specific areas and content modification to put something inside
why do we need delivery vehicles?
delivery to target site, drug stability, biocompatibility, reduced non-target site toxicity
how small are exosomes?
50-150 nanometers
content loading strategy at parent cell level
genetic engineering, direct co-culture
content loading strategy at EVs level
co-incubation, extrusion, freeze-thaw, electroporation
surface engineering at parental cell level
constant harvest but time consuming
surface engineering EVs level
more simplicity but limited numbers
main synthetic nanoparticle
liposome
pros and cons of natural EVs
biocompatibility and considered as waste for GMP cell production, but batch to batch variation in size, concentration, exact function
liposomes pros vs cons
consistency in production and easy to produce, but lack natural tissue tropism
how can nanoparticles be seen?
TEM, nuclear imaging, fluorscent protein and organic fluorescent dye
degenerative joint disease/osteoarthritis
always secondary in animals with a direct cause
pathophysiology of secondary DJD
altered stress on articular cartilage → chondrocyte damage → proinflammatory mediators → synovial inflammation, thinner joint fluid and cartilage damage → altered stress on articular cartilage
proinflammatory mediators
pro-inflammatory cytokines, proteolytic enzymes, interleukins, prostaglandins, nitric oxide, nerve growth factors
types of DJD treatments
symptomatic, salvage, and SMOADs/DMOADs
symptomatic DJD treatments
physical therapy, nutraceuticals, analgesics, intra-articular analgesia
salvage DJD treatments
joint replacement surgeries, preventative surgery
structure/disease modifying OA drugs
halt/reverse inflammatory cascade and delay/stabilize/reverse cartilage/synovial damage, viscosupplementation, platelet rich plasna, mesenchymal stem cells, and stromal vascular fraction
platelet rich plasma
higher concentration of platelets injected intra-articularly, need to purify blood so only platelets, can have adverse effects, good short-term, but limited long term assesment
mesenchymal stem cells
from bone marrow or fat, takes a while to purify and grow stem cells, injected intra-articularly, but many different risks including oncogenic effects
stromal vascular fraction
has more cellular components, can be done quickly, faster effects than MSC but not sustained
challenges with designing a study
dog variations, using multiple treatments and causing confounding factors, differences in severity of disease between dogs
blood-derived orthobiologics
platelet-rich plasma, autologous conditioned serum, autologous protein solution, alpha-2 macroglobulin
cell/marrow-based orthobiologics
bone marrow aspirate concentrate and MSCs
tissue allografts and emerging orthobiologics
amniotic tissue allograft, extracellular vesicles/secretome products, and lyophilized cell-free preparations
uses and limitations of PRP in horses
intralesional tendonitis and intra-articular OA, no standardized dose or leukocyte concentration
ACS/IRAP
monocytes from horse blood conditioned on glass beads, high IL-1ra, 24 h processing, used for synovitis/OA, multiple doses per kit than can be frozen
APS/pro-stride
concentrate of WBCs, platelets and plasma proteins, high IL-1ra and growth factors, mainly for OA, single dose per kit
alpha-2 macroglobulin
protease inhibitor and cytokine modulator, multiple doses possible, can be frozen, mainly for OA/synovitis
BMAC
centrifugation of patient bone marrow with MSCs, platelets, leukocytes, and high IL-1ra, for OA, cystic lesions, soft tissue injuries, needs to be collected under anesthesia
MSCs horse lesion evidence
for reduced reinjury, not return to work or healing
renovo/aminotic tissue allograft
off the shelf, rich in il-1ra, growth factors, supplements and protects tissues, for tendonitis and soft tissue injuries, limited control trials
extracellular vesicles/secretomes for horses
off the shelf, cell-free, very early stages
tissue engineered heart valves
for children so that they can grow with the child, can come from valve endothelial cells, valve interstitial cells, mesenchymal stem cells, or mononuclear cells
what heart valve is most affected with children?
aortic/pulmonary semilunar valves
what does anisotropic mean?
heart valves have different properties and forms depending on the direction
mechanical valve substitutes
excellent durability and function, but require lifelong anticoagulation therapy
bioprosthetic valve substitutes
good durability and function, but may require anticoagulation therapy for a period, and prone to calcification
homograft substitute
good durability, function, and surgical flexibility, but may calcify
scaffold
will be decellularized or polymer, maintains shape and mechanical support as tissue develops
decellularized heart valve
removal of cells, DNA, and GAGs, will still have most of ECM, collagen, elastin, and basement membrane
four steps of evaluating valve performance
component mechanical behavior → composition analysis → intact valve performance → and large animal models
planar biaxial testing
pull from all four sides, decellularization has significant stretch and arial strain due to space from cell removal
stress relaxation
measure of the time dependent response of the leaflet, shows how leaflet handles sustained load, significant reduction in decellularization
in vivo valve performance
in 20-week sheep juvenile model to mainly show calcification largely decreased in decellularization
pulsatile conditioning
will cause cells to migrate into other parts of tissue
cancer
an umbrella term for a large and diverse group of over 100 diseases
cancer core mechanism
has uncontrolled growth, no maturation, and cell death processes are lost
why is cancer a stem cell disease?
stem cells will acquire changes in cancer that disregulate their processes and may escape their niche
benign tumor vs malignant
benign grow more slowly and do not metastatasize, while malignant tumors do
first line cancer treatments
surgery, radiation, immunotherapy, chemotherapy, targeted therapies, and hormone therapy
lymphoma
blood cell tumor featuring B or T cell lymphocytes, tell which one with flow cytometry markers
R-CHOP
first line treatment for B-cell cancer, cures 50-70%, mainly targets DNA
CAR-T
engineered T cells that target B-cell lymphoma with lentivirus, used as a second-line/rescue treatment, main adverse events are CRS and ICANS
melanoma
solid tumor from melanocytes, abnormal pigemented mole/skin patch, first line treatments are anti PD-1 and MEK inhibitors, second line treatment is TIL
TIL
obtain and grow tumor-reactive TILs from body, infuse with IL-2s into patient to kill tumor